Hanjie Liu
Capital Medical University
14 Papers
7 Citations
Hanjie Liu is an academic researcher from Capital Medical University. The author has contributed to research in topics: Glioma & Medicine. The author has an hindex of 4, co-authored 7 publications.
Chat about Author
Papers
MGMT genomic rearrangements contribute to chemotherapy resistance in gliomas
Barbara Oldrini,Nuria Vaquero-Siguero,Quanhua Mu,Paula Kroon,Ying Zhang,Marcos Galán-Ganga,Zhaoshi Bao,Zhaoshi Bao,Zheng Wang,Hanjie Liu,Jason K. Sa,Jason K. Sa,Junfei Zhao,Hoon Kim,Sandra Rodriguez-Perales,Do Hyun Nam,Roel G.W. Verhaak,Raul Rabadan,Tao Jiang,Jiguang Wang,Massimo Squatrito +20 more
TL;DR: It is shown that some recurrent gliomas harbour O-6-methylguanine-DNA methyltransferase (MGMT) genomic rearrangements, and in vitro and in vivo these contribute to temozolomide resistance.
Ferroptosis-Related Gene Signature Predicts Glioma Cell Death and Glioma Patient Progression.
Hanjie Liu,Huimin Hu,Guanzhang Li,Ying Zhang,Fan Wu,Xiu Liu,Kuanyu Wang,Chuanbao Zhang,Tao Jiang +8 more
TL;DR: Functional assays in glioma cell lines indicated the association of ferroptosis with temozolomide resistance, autophagy, and gliomas cell migration, and the identified ferroPTosis-related genes were significantly correlated with gli cancer progression.
Molecular subtyping reveals immune alterations in IDH wild-type lower-grade diffuse glioma
Fan Wu,Guanzhang Li,Hanjie Liu,Zheng Zhao,Rui-Chao Chai,Yu-Qing Liu,Haoyu Jiang,You Zhai,Yuemei Feng,Renpeng Li,Wei Zhang +10 more
TL;DR: A robust gene expression‐based molecular classification of IDH wild‐type diffuse LGG into two subtypes with distinct biological and clinical features is presented and a five‐gene signature is developed and validated for better application of this acquired stratification.
61
Prognostic Correlation of Autophagy-Related Gene Expression-Based Risk Signature in Patients with Glioblastoma.
TL;DR: A novel autophagy-related signature for the prediction of prognosis in patients with glioblastoma is identified and survival analysis indicated that patients in the high-risk group had dramatically shorter overall survival compared with their low-risk counterparts.
Polo-like kinases as potential targets and PLK2 as a novel biomarker for the prognosis of human glioblastoma
TL;DR: It is suggested that PLKs might be useful molecular indicators as well as prospective treatment targets for GBM and a PLK2 inhibitor has been studied for the first time in a glioma cell in this work.